Clinical Trial Detail

NCT ID	NCT02446600
Title	Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment	Active, not recruiting
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	ovarian cancer fallopian tube cancer peritoneum cancer fallopian tube serous adenocarcinoma peritoneal carcinoma endometrioid ovary carcinoma peritoneal serous adenocarcinoma fallopian tube clear cell adenocarcinoma ovarian serous carcinoma ovarian clear cell carcinoma fallopian tube endometrioid adenocarcinoma
Therapies	Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin
Age Groups:	adult senior